{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:27:20Z","timestamp":1793896040739,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22505023"],"award-info":[{"award-number":["22505023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Sichuan Province Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["CSTB2025TIAD-KPXO090"],"award-info":[{"award-number":["CSTB2025TIAD-KPXO090"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["CSTB2025TIAD-QQZDQXXCZXBFFX0007"],"award-info":[{"award-number":["CSTB2025TIAD-QQZDQXXCZXBFFX0007"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-MSX1002"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX1002"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-LZX0055"],"award-info":[{"award-number":["CSTB2024NSCQ-LZX0055"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC2000"],"award-info":[{"award-number":["2023NSFSC2000"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110091","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:34:19Z","timestamp":1781278459000},"page":"110091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of selective CDK9 degraders with anti-AML activity using PROTAC technology"],"prefix":"10.1016","volume":"180","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110091_bb0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110091_bb0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.bioorg.2026.110091_bb0015","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1073\/pnas.91.9.3834","article-title":"Pitalre, a nuclear cdc2-related protein-kinase that phosphorylates the retinoblastoma protein in-vitro","volume":"91","author":"Grana","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110091_bb0020","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41401-021-00796-0","article-title":"Targeting cyclin-dependent kinase 9 in cancer therapy","volume":"43","author":"Shen","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2026.110091_bb0025","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.29736","article-title":"Cdk9-dependent rna polymerase ii pausing controls transcription initiation","volume":"6","author":"Gressel","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2026.110091_bb0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","article-title":"Controlling the elongation phase of transcription with p-tefb","volume":"23","author":"Peterlin","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.110091_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2219470","article-title":"Targeting cdk9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments","volume":"24","author":"Xiao","year":"2023","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2026.110091_bb0040","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110091_bb0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2026.110091_bb0050","doi-asserted-by":"crossref","first-page":"D1034","DOI":"10.1093\/nar\/gks1021","article-title":"Hemaexplorer: a database of mrna expression profiles in normal and malignant haematopoiesis","volume":"41","author":"Bagger","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110091_bb0055","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006353008903","article-title":"Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials","volume":"17","author":"Senderowicz","year":"1999","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.110091_bb0060","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2015.125849","article-title":"Randomized multicenter phase ii study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (flam) versus cytarabine\/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia","volume":"100","author":"Zeidner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.110091_bb0065","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-DDT02-02","article-title":"Abstract DDT02-02: BAY 1143572: a first-in-class, highly selective, potent and orally available inhibitor of PTEFb\/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis","volume":"75","author":"Scholz","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110091_bb0070","doi-asserted-by":"crossref","first-page":"7609","DOI":"10.1021\/acs.jmedchem.5b01294","article-title":"Correction to N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent","volume":"58","author":"Misra","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110091_bb0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1039\/D2MD00040G","article-title":"Cdk9 inhibitors in cancer research","volume":"13","author":"Huang","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110091_bb0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tips.2008.03.003","article-title":"Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology","volume":"29","author":"Wang","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.110091_bb0085","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110091_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202207778","article-title":"Targeted protein degradation technology and nanomedicine: powerful allies against cancer","volume":"19","author":"Lin","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.bioorg.2026.110091_bb0095","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin\u2013proteasome system (ups) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110091_bb0100","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the skp1-cullin-f box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110091_bb0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"Protac targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110091_bb0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110091_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of protacs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.bioorg.2026.110091_bb0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (protac) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110091_bb0125","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"Protacs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110091_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-022-01258-8","article-title":"A proteolysis-targeting chimera molecule selectively degrades enl and inhibits malignant gene expression and tumor growth","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110091_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado1432","article-title":"A potent and selective enl degrader suppresses oncogenic gene expression and leukemia progression","volume":"10","author":"Xue","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110091_bb0140","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of cdk9 by a proteolysis targeting chimera (protac)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bioorg.2026.110091_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128061","article-title":"Aminopyrazole based cdk9 protac sensitizes pancreatic cancer cells to venetoclax","volume":"43","author":"King","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110091_bb0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of cdk9 using selective cdk9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110091_bb0155","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.3390\/ijms23105476","article-title":"Antitumoral activity of a cdk9 protac compound in her2-positive breast cancer","volume":"23","author":"Noblejas-L\u00f3pez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110091_bb0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bioorg.2018.08.028","article-title":"Discovery of wogonin-based protacs against cdk9 and capable of achieving antitumor activity","volume":"81","author":"Bian","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110091_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective cdk9 degraders with enhancing antiproliferative activity through protac conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110091_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114792","article-title":"Modulation of flt3-itd and cdk9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (protac)","volume":"243","author":"Reznickova","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110091_bb0175","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1073\/pnas.76.11.5750","article-title":"Early termination of heterogeneous nuclear-rna transcripts in mammalian-cells - accentuation by 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole","volume":"76","author":"Tamm","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110091_bb0180","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/S0021-9258(18)94169-4","article-title":"5,6-dichloro-1-\u03b2-d-ribofuranosylbenzimidazole inhibits transcription elongation by rna polymerase ii in vitro","volume":"264","author":"Chodosh","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110091_bb0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1471-2407-9-281","article-title":"The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-d-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status","volume":"9","author":"Turinetto","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110091_bb0190","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1038\/sj.onc.1202961","article-title":"Rna synthesis block by 5,6-dichloro-1-\u03b2-d-ribofuranosylbenzimidazole (drb) triggers p53-dependent apoptosis in human colon carcinoma cells","volume":"18","author":"Poele","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110091_bb0195","doi-asserted-by":"crossref","first-page":"12621","DOI":"10.1038\/s41598-023-39340-x","article-title":"5,6-dichloro-1-\u03b2-d-ribofuranosylbenzimidazole (drb) induces apoptosis in breast cancer cells through inhibiting of mcl-1 expression","volume":"13","author":"Kuo","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110091_bb0200","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","article-title":"Seliciclib (cyc202, r-roscovitine) induces cell death in multiple myeloma cells by inhibition of rna polymerase ii-dependent transcription and down-regulation of mcl-1","volume":"65","author":"MacCallum","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110091_bb0205","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bmcl.2011.12.088","article-title":"Synthesis and biological evaluation of benzo imidazole derivatives as potential anti-cancer agents","volume":"22","author":"Alkahtani","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110091_bb0210","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.chembiol.2010.07.012","article-title":"Halogen bonds form the basis for selective p-tefb inhibition by drb","volume":"17","author":"Baumli","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110091_bb0215","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cmdc.201700447","article-title":"Identification of atuveciclib (bay 1143572), the first highly selective, clinical ptefb\/cdk9 inhibitor for the treatment of cancer","volume":"12","author":"L\u00fccking","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110091_bb0220","doi-asserted-by":"crossref","first-page":"16428","DOI":"10.1021\/jacs.8b10320","article-title":"Enhancing antiproliferative activity and selectivity of a flt-3 inhibitor by proteolysis targeting chimera conversion","volume":"140","author":"Burslem","year":"2018","journal-title":"J. Am. Chem. Soc."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:03:12Z","timestamp":1793894592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826006279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S0045206826006279"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110091","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of selective CDK9 degraders with anti-AML activity using PROTAC technology","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110091"}}